Nishant Narayanan Vaikath | Hamad Bin Khalifa University

Qatar Biomedical Research Institute QBRI

GO
SVG sprite APPLY NOW
  • Menu
  • Search
  • Resources
Hamad Bin Khalifa University

FACULTY BIOGRAPHIES

Nishant Narayanan Vaikath

Dr. Nishant Narayanan Vaikath

Research Associate
Neurological Disorders Research Center
Qatar Biomedical Research Institute
  • Phone44541435

Biography

Dr. Vaikath obtained his Master’s degree in Biotechnology from Periyar University, India in 2004 and, in 2019 completed his PhD in Medical Science from Lund University, Sweden at the faculty of Medicine in the subject Biomedicine, Neuroscience. After completion of his Master’s degree he worked in biotech industry for 5 years in India. He was involved in expression and purification of recombinant proteins associated with diseases like HIV and HCV to use in diagnostic kits. In 2006, he moved to Abexome Biosciences Pvt. Ltd, India where he worked with the antibody development team and later went on to lead a group involved in the development of monoclonal and polyclonal antibodies for various peptides and proteins involved in cancer, diabetes and neurological disorders. In 2010, he moved to the College of Medicine and Health Sciences, United Arab Emirates University, UAE where he worked on generation and characterization monoclonal and polyclonal antibodies against various proteins involved neurological disorders like Alzheimer’s disease and Parkinson’s disease. In 2016, he joined QBRI in Prof. Omar El-Agnaf’s laboratory as Research Associate.

Research Interests

Vaikath’s main research interest involves antibody generation, protein engineering, nanobodies as tools for diagnosis and therapy for neurodegenerative diseases and Immunotherapeutic approach for neurological disorders. 

  • Developing disease conformation-specific antibodies for a-synuclein pathology as novel tools for therapeutics and diagnosis.
  • Developing scFv based fusion protein for targeting pathogenic a-synuclein in the brain.
  • Generation and identification of nanobodies targeting pathogenic forms of proteins involved in neurodegenerative disorders.

Selected Publications

  • Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer LD, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

    Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation. 2018 May 1;15(1):129. doi: 10.1186/s12974-018-1171-z. PubMed PMID: 29716614.

     2018

  • Sharrad DF, Chen BN, Gai WP, Vaikath N, El-Agnaf OM, Brookes SJ.

    Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum. Neurogastroenterol Motil. 2017 Apr;29(4). doi: 10.1111/nmo.12985. Epub 2016 Nov 7. PubMed PMID: 27997067.

     2016

  • Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah M, Varghese S, Haque ME, Tokuda T, Auinger P, Calabresi P, Parnetti L, El-Agnaf OM.

    Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. Mov Disord. 2016 Oct;31(10):1535-1542. doi: 10.1002/mds.26754. PubMed PMID: 27548849.

     2016

  • Kim DK, Lim HS, Kawasaki I, Shim YH, Vaikath NN, El-Agnaf OM, Lee HJ, Lee SJ.

    Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. Autophagy. 2016 Oct 2;12(10):1849-1863. Epub 2016 Aug 2. PubMed PMID: 27485532; PubMed Central PMCID: PMC5079673.

     2016

  • Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WD, El-Agnaf OM.

    Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener. 2016 Jan 19;11:7. doi: 10.1186/s13024-016-0072-9. PubMed PMID: 26782965; PubMed Central PMCID: PMC4717559.

     2016

  • Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DM, Imai Y, Halliday GM, Li JY, El-Agnaf OM.

    Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30. PubMed PMID: 25937088.

     2015

  • Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA.

    Antibodies against alpha-synuclein: tools and therapies. J Neurochem. doi: 10.1111/jnc.14713. [Epub ahead of print]

    2019

  • Vaikath NN, Erskine D, Morris CM, Majbour NK, Vekrellis K, Li JY, El-Agnaf OMA.

    Heterogeneity in α-synuclein sub-types and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. Neuropathol Appl Neurobiol. 2018 Nov 13. doi: 10.1111/nan.12531. [Epub ahead of print] PubMed PMID: 30422353.

     2018

  • Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M et al.

    Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain. 2019 May 1;142(5):1365-1385. doi: 10.1093

     2019
X

X